Marketability of a Technology-based Intervention to Increase HPV Vaccination

Sponsor
Real Prevention, LLC (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT03497936
Collaborator
University of California, Irvine (Other)
360
7
2
34.9
51.4
1.5

Study Details

Study Description

Brief Summary

The overall goal of this SBIR Phase II project is to reduce cancer rates by marketing a brief, easily implemented technology-based intervention that increases human papillomavirus (HPV) vaccination among Planned Parenthood and other clients. The intervention's innovative technology allows for the investigators' narrative videos to be presented along will reminder texts. It will be evaluated for use in waiting rooms and promises to overcome vaccination barriers among high risk but underserved low SES and minority populations.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Women's Stories
N/A

Detailed Description

The purpose of this Phase II research project is to evaluate and market an innovative health message intervention to increase uptake of the human papillomavirus (HPV) vaccine and reduce women's cervical cancer risk through partnership with Planned Parenthood. The overall aim is to reach a broad population through Planned Parenthood, the nation's leading sexual and reproductive health care center, especially among low socioeconomic status (SES) and historically underserved populations. Despite an overall increase in vaccination and reduction in HPV-related infections in younger populations targeted by previous health promotion efforts, young adult women who are recommended for vaccination demonstrate much lower vaccination rates and higher rates of infection. In a recent Phase I grant, the investigators developed and demonstrated the usability and feasibility of an innovative, culturally-grounded, technology-based narrative intervention that delivers decision narratives in the form of videos via a health kiosk, an underutilized communication strategy for reaching less involved audiences. This brief, low-cost, easily implementable intervention doubled the uptake of the vaccine in a separate pilot study. The proposed Phase II project will: (1) Complete development of the intervention, (2) Evaluate its effectiveness through a randomized clinical trial, and (3) Prepare the product for the market. To accomplish these aims, the investigators will develop the intervention for implementation in waiting rooms as part of check-in procedures. Development includes programming and installing tablets to accomplish these tasks (Aim 1). The investigators will then conduct the evaluation study in four Planned Parenthood clinics in southeastern Pennsylvania (Aim 2). Eligible women will be consented, complete a pretest, and then randomized to view the brief intervention or attention control messages via the tablet. After viewing the messages, the participants will complete a short posttest. Treatment participants will receive follow up texts/emails as reminders to vaccinate, and all participants will receive texts/emails with links that allow completion of posttest surveys at 3- and 9 months. Finally, the investigators will prepare the intervention for the market that includes not only Planned Parenthood but other clinics that are currently served by the project partners as well as the broader market for HPV vaccination (Aim 3). In summary, the proposed communication strategy has wide reaching implications not only for reducing cancer risk, but more broadly for designing brief and easily implemented prevention messages across many domains of public health. The research will also close the health disparities gap in minority, under-served young adult women's access to preventive health care.

Study Design

Study Type:
Interventional
Actual Enrollment :
360 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants randomly assigned to one of two arms (intervention, no intervention). Intervention participants receive Women's Stories. No intervention participants receive treatment as usual. All participants are administered a pretest and two post tests, and clinical records are examined for vaccination outcomes.Participants randomly assigned to one of two arms (intervention, no intervention). Intervention participants receive Women's Stories. No intervention participants receive treatment as usual. All participants are administered a pretest and two post tests, and clinical records are examined for vaccination outcomes.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Marketability of a Technology-based Intervention to Increase HPV Vaccination
Actual Study Start Date :
May 1, 2018
Anticipated Primary Completion Date :
Mar 29, 2021
Anticipated Study Completion Date :
Mar 29, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Women's Stories

Participants in this group will be randomly assigned to use the Women's Stories intervention.

Behavioral: Women's Stories
Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.

No Intervention: Programming as usual

Participants in this group will be randomly assigned participate in their usual programming.

Outcome Measures

Primary Outcome Measures

  1. HPV Vaccination [9 months]

    Uptake of HPV Vaccine as measured by medical records review and self report

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 26 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • All English-speaking women clients of 4 Planned Parenthood clinics who are between 18 and 26 and have not been vaccinated.
Exclusion Criteria:
  • Men, women who do not speak English or are not between 18 and 26 years old, anyone not a client of the 4 Planned Parenthood clinics.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California, Irvine Irvine California United States 92697-7700
2 Planned Parenthood of Illinois Chicago Illinois United States 60603
3 Planned Parenthood of the St. Louis Region and Southwest Missouri Saint Louis Missouri United States 63108
4 REAL Prevention LLC Clifton New Jersey United States 07013
5 Public Health Management Corporation Philadelphia Pennsylvania United States 19102
6 Planned Parenthood of Southeastern Pennsylvania Philadelphia Pennsylvania United States 19107-6734
7 St. Andrew Development York Pennsylvania United States 17401-3333

Sponsors and Collaborators

  • Real Prevention, LLC
  • University of California, Irvine

Investigators

  • Principal Investigator: Michael Hecht, Ph.D., Real Prevention, LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Real Prevention, LLC
ClinicalTrials.gov Identifier:
NCT03497936
Other Study ID Numbers:
  • R44DP006291
First Posted:
Apr 13, 2018
Last Update Posted:
Oct 19, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Real Prevention, LLC
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 19, 2020